Neuralink is building an implant that lets people with paralysis control a computer with their thoughts. Investor interest is high, and “where can I buy Neuralink shares” is one of the most common questions asked about the company.
The short answer
You cannot. This article explains why, how much the company has taken from investors and what it has actually delivered in that time. It also covers where an investor can go if what interests them is the field rather than this one company.
Why the shares cannot be bought
There is no ban on trading them. Three reasons stack up.
The company is private. Neuralink has never floated. It has no ticker and no ISIN, so there is nothing to type into a broker app.
Secondary markets require US accredited status. Platforms such as Forge Global, EquityZen and Nasdaq Private Market do broker shares in private companies, but only to so-called accredited investors as the United States defines them. That means income above $200,000 a year for two years running, or net worth above $1 million excluding your home. An ordinary retail investor does not clear that bar.
This is an American rule attached to American private securities, so it applies whoever the buyer is and wherever they live. Britain has its own categories for high net worth individuals and self-certified sophisticated investors, but those sit inside the FCA’s financial promotion rules at home and use different thresholds. Meeting them does not make anyone accredited in the eyes of the US regulator.
The tickets are large. Even someone who does qualify runs into minimum trade sizes in the tens of thousands of dollars.
How much the company has raised
This is the one part of the story with hard numbers. Neuralink has to report every round to the US Securities and Exchange Commission on a Form D, which states the amount subscribed.
| Round | Year | Amount subscribed |
|---|---|---|
| Series A | 2017 | $27.0 million |
| Series B | 2019 | $39.3 million |
| Series C | 2021 | $205.9 million |
| Series D | 2023 | $323.2 million |
| Series E | 2025 | $649.0 million |
That comes to $1.244 billion in total. The Series C round was led by Vy Capital, and the other investors include Google Ventures, DFJ Growth, Valor Equity Partners, Craft Ventures, Founders Fund and Gigafund. The most recent round, in June 2025, drew 49 investors including ARK Invest, Sequoia Capital, Thrive Capital and the Qatari sovereign fund QIA.
What the company has actually achieved
Money is one thing, results another. Here the progress since 2024 has been considerable.
Neuralink performed its first implant in a human on 28 January 2024, and Elon Musk announced it publicly the following day. The patient was Noland Arbaugh, a man left paralysed after an accident.
As of 28 January 2026 the company reports 21 participants enrolled in its studies. Clinical trials are running in four countries: the United States, Canada, the United Arab Emirates and the United Kingdom. The clinical trials registry lists six of them, with a combined target of 47 participants.
What the company does not yet have matters just as much. The FDA has granted Breakthrough Device designation to two programmes, the Blindsight system for restoring vision and a speech restoration programme. That only means a faster line to the regulator, not permission to sell. In the FDA database Neuralink holds no marketing authorisation of any kind. To this day the implant is used solely inside clinical trials.
What the shares fetch away from an exchange
Nasdaq Private Market puts the value of a Neuralink share at $227.88 as of 22 July 2026. It is worth understanding what that number is and what it is not.
The platform labels it explicitly as its own estimate, not a price from a completed trade. It comes out of a model, not from buyers and sellers meeting on an exchange. What it lacks is the thing that makes a market price a market price: enough volume and a public order book.
So it does not work as a comparison with a listed company. With a listed business you know how many shares exist and what they are changing hands for right now. With Neuralink you know neither.
Is an IPO on the way
As of August 2026 there is no public sign of one, and this is more than a “we found nothing” claim.
Across its whole existence Neuralink has filed six documents with the US Securities and Exchange Commission, and every one of them is a Form D, the notice of a private offering. The S-1 registration statement that starts a flotation has never been filed, not even confidentially. The most recent filing of any kind dates from June 2025.
SpaceX is listed, Neuralink is not
This is where the most common mix-up happens. SpaceX listed on Nasdaq in June 2026, and plenty of people assume that buying it buys a slice of Musk’s empire, Neuralink included.
It does not. They are two separate companies with separate ownership. We checked this in SpaceX’s own filings. In the quarterly report for the second quarter of 2026, Neuralink does not appear once. In the listing prospectus it is mentioned three times, and only in management biographies and in the risk factors. There is no ownership stake.
An investor can buy SpaceX shares. What those shares will not give them is exposure to Neuralink.
Where an investor can actually go
Not to Neuralink. To the field, yes.
| Company | Ticker | Exchange |
|---|---|---|
| ONWARD Medical | ONWD | Euronext Amsterdam and Brussels |
| NeuroPace | NPCE | Nasdaq |
| Medtronic | MDT | NYSE |
| Abbott | ABT | NYSE |
| Boston Scientific | BSX | NYSE |
| LivaNova | LIVN | Nasdaq |
ONWARD Medical is a Dutch company with its own programme linking the brain and the spinal cord, which makes it the closest European equivalent of the subject. NeuroPace makes an implantable neurostimulator for epilepsy and is often described as the only listed commercial company of its kind in the United States. The other four names are large medical device makers with neuromodulation divisions, where this area is only a sliver of revenue.
The rivals that are not listed either
Neuralink is not alone in the field, and some competitors are further along with the regulators.
Synchron places its implant through a blood vessel, with no need to open the skull, and has raised roughly $345 million. Precision Neuroscience, founded by Neuralink co-founder Benjamin Rapoport, has an implant that sits on the surface of the brain and is the furthest along in regulatory terms of the whole field. Paradromics has bet on high data throughput and in 2025 carried out its first recording from a human brain.
Blackrock Neurotech is the oldest player in the field, and researchers have been using its electrode arrays for decades. In 2024 it was taken over by Tether, the stablecoin issuer. The newest challenger is Sam Altman’s Merge Labs, in which OpenAI wrote the largest cheque.
None of these companies is publicly traded. The field as a whole is still at the venture capital stage, and for a retail investor it stays shut.
What this means in practice
Anyone who wants Neuralink in a portfolio has to wait for an IPO that nobody has announced. Anyone who wants the field can look at the listed companies in the table above, while accepting that at the large manufacturers neurotechnology is only a small part of the business.
The figures in this article are as of the last update, and with a private company they can change without any public announcement.